Applying the Market Approach to Pre-IPO Valuation: Comparable Public Companies and Recent Transaction Multiples

The SFC’s December 2024 consultation on the Code of Conduct for Sponsors—specifically its proposed tightening of sponsor liability for pre-IPO valuations—has shifted the ground for every party involved in a Hong Kong listing. Under the proposed amendments, a sponsor must now demonstrate that it has applied “reasonable due diligence” to the valuation methodologies underpinning the price per share in the final pre-IPO round, not merely to the financial projections. This places the market approach—valuing a private company by reference to listed peers and recent private transactions—squarely in the crosshairs of regulatory scrutiny. For a CFO preparing a Main Board application in 2025, the days of citing a single revenue multiple from a US-listed comparable are over. The HKEX and the SFC now expect a documented, multi-source triangulation that reconciles the company’s pre-money valuation with observable public market data. This article dissects the mechanics of applying the market approach to a pre-IPO valuation, using real 2024-2025 transaction data and HKEX Listing Rules Chapter 11 requirements as the analytical framework.

The Regulatory Baseline for Pre-IPO Valuation in Hong Kong

Sponsor Due Diligence under the SFC Code of Conduct

The SFC’s Code of Conduct for Sponsors (paragraph 17.1 and the associated “Guidance Note on Due Diligence”) has long required a sponsor to form a “reasonable opinion” on the fairness of the valuation in a listing applicant’s pre-IPO share issuances. The 2024 consultation proposal, however, goes further: it explicitly requires the sponsor to document the valuation methodology used for each pre-IPO round within the track record period (typically the two financial years preceding the listing application). For a company that raised a Series C at a HKD 2.0 billion pre-money valuation in Q3 2024, the sponsor must now produce a written analysis showing how that multiple aligns with the median price-to-sales (P/S) or enterprise-value-to-EBITDA (EV/EBITDA) ratios of a defined peer group of Hong Kong Main Board and GEM listed companies.

The practical implication is that a sponsor cannot accept the company’s internal valuation at face value. The sponsor’s own financial advisory team—or a third-party valuation firm engaged under the sponsor’s supervision—must construct a comparable company analysis (CCA) that meets the “reasonable basis” test. The SFC has indicated it will review this analysis as part of the listing application vetting, and any material deviation from the peer group median without a documented justification (e.g., a growth premium or a liquidity discount) will trigger a deficiency letter.

HKEX Listing Rules Chapter 11 and the “Fair and Reasonable” Standard

HKEX Listing Rule 11.04 requires that a listing applicant’s securities be issued at a price that is “fair and reasonable” to all shareholders, with the burden of proof falling on the sponsor. In practice, the Exchange examines the pricing of the last pre-IPO round against the final offer price in the IPO prospectus. If the discount from the pre-IPO price to the IPO price exceeds 30%, the Exchange will typically require a detailed explanation and may request a valuation report from an independent expert. The SFC’s 2024 consultation reinforces this by stating that a discount exceeding 40% “raises a presumption that the pre-IPO valuation was not supported by reasonable market evidence.”

For a company targeting a Main Board listing in H2 2025, this means the pre-IPO valuation must be calibrated to a range that leaves a discount of no more than 25-35% to the expected IPO price—a band that requires the market approach to be applied with precision. A CFO cannot simply take the last round’s price and add a 20% “IPO premium”; the Exchange will demand a peer-group analysis that supports the implied forward multiples.

Constructing a Credible Comparable Company Analysis (CCA)

Defining the Peer Group: Sector, Size, and Listing Venue

The first step in a defensible CCA is to define a peer group that is both relevant and sufficiently large to produce statistically meaningful multiples. For a Hong Kong-listed pre-IPO company in the healthcare technology sector, the peer group should include at least eight to twelve Main Board-listed companies with a market capitalisation within a 0.5x to 2.0x band of the applicant’s expected post-money valuation. The SFC’s guidance note on “Comparable Company Analysis” (issued in 2022 and updated in the 2024 consultation materials) explicitly warns against including companies that are not “reasonably comparable” in terms of revenue scale, growth rate, and business model.

As of Q1 2025, the median EV/EBITDA multiple for Hong Kong-listed healthcare technology companies with a market cap between HKD 1.0 billion and HKD 5.0 billion stands at 14.2x, based on Bloomberg data for the twelve months ended 31 December 2024. For a pre-IPO company with an EBITDA of HKD 80 million in FY2024, this implies an enterprise value of approximately HKD 1.136 billion. If the company’s last pre-IPO round valued it at an EV of HKD 1.5 billion—a 32% premium to the peer median—the sponsor would need to document a specific growth premium, such as a revenue CAGR above 40% versus the peer group median of 22%, or a unique technology patent that justifies a higher multiple.

The choice of listing venue also matters. A company that will list on the Main Board should use Main Board comparables, not GEM-listed peers, because the liquidity and institutional investor base differ materially. GEM-listed companies in the same sector trade at a median discount of 28% to Main Board peers in terms of P/S multiple, according to HKEX data from its 2024 Market Statistics report. Using GEM comparables without adjusting for this discount would produce an undervalued benchmark, potentially triggering a deficiency letter from the Exchange.

Adjusting for Size, Growth, and Liquidity Premiums

No two companies are identical, and the CCA must include explicit adjustments for size, growth, and liquidity. The standard methodology in Hong Kong sponsor practice is to apply a size premium or discount based on the market capitalisation differential. The Duff & Phelps (now Kroll) 2024 “Size Premium Study” for the Hong Kong market shows that companies with a market cap below HKD 2.0 billion carry an average size premium of 2.5 percentage points over the cost of equity, which translates into a 10-15% discount on the EV/EBITDA multiple relative to larger peers.

For a pre-IPO company with a HKD 1.5 billion expected market cap, the sponsor should apply a size discount of approximately 12% to the peer group median EV/EBITDA. This yields an adjusted benchmark of 12.5x (14.2x x 0.88), or an implied enterprise value of HKD 1.0 billion. If the company’s actual pre-IPO valuation is higher, the sponsor must document a compensating growth premium—for example, a projected three-year revenue CAGR of 45% versus the peer median of 25%, which would justify a 20-25% premium on the multiple.

Liquidity is a separate adjustment. Pre-IPO shares are inherently illiquid, and the Hong Kong market convention—supported by the SFC’s 2023 “Guidance Note on Valuation of Unlisted Securities”—is to apply a liquidity discount of 20-30% to the public market multiple. This means that even if the public peer group trades at 14.2x EV/EBITDA, the pre-IPO valuation should use a range of 9.9x to 11.4x (14.2x x 0.70 to 14.2x x 0.80) before any growth premium is added. A sponsor that fails to apply this discount and instead uses the raw public multiple will produce a pre-IPO valuation that is systematically too high, creating a discount problem at the IPO pricing stage.

Recent Transaction Multiples: The Second Pillar of the Market Approach

Sourcing and Validating Private Transaction Data

The second component of the market approach is the analysis of recent transaction multiples—pre-IPO private placements, secondary block trades, and M&A transactions involving comparable companies. This data is harder to source than public market pricing because private transactions in Hong Kong are not systematically reported. The practical sources include: (1) the HKEX’s “Disclosure of Interests” filings under the Securities and Futures Ordinance (Cap. 571), which capture substantial shareholder changes in listed companies and can reveal private placement pricing; (2) the SFC’s “Corporate Finance Adviser” database, which records sponsor-led pre-IPO rounds; and (3) commercial databases such as Preqin and PitchBook, which track private equity and venture capital rounds in Asia.

For a pre-IPO company in the fintech sector, the relevant transaction window is typically the 12 to 18 months preceding the listing application. As of Q1 2025, the median pre-money valuation for Series C fintech rounds in Hong Kong was HKD 1.8 billion, based on PitchBook data covering 14 transactions closed between January 2024 and December 2024. The median revenue multiple for these rounds was 8.5x forward revenue, compared to 6.2x for public fintech peers on the Main Board. The premium of 37% reflects the growth expectations embedded in private rounds, but it also creates a risk: if the public market multiples contract, the pre-IPO valuation may become unsustainable.

The key validation step is to compare the transaction multiple from the company’s own pre-IPO round against the median of comparable transactions. If the company’s Series C valued it at 10.0x forward revenue—18% above the peer transaction median of 8.5x—the sponsor must document a specific rationale, such as a binding commercial contract with a major bank or a regulatory licence that the peer companies lack. Without such documentation, the SFC may deem the valuation “not supported by market evidence” and require a downward adjustment before the listing application proceeds.

Reconciling Public and Private Multiples: The Triangulation Method

The most defensible approach under the 2024-2025 regulatory framework is the “triangulation method,” which combines the public CCA, the private transaction analysis, and a third data point—such as a discounted cash flow (DCF) model or a precedent transaction analysis—to produce a range. The sponsor then selects a point within that range that is supported by the strongest evidence.

For example, consider a pre-IPO healthcare technology company with the following inputs:

• Public CCA median EV/EBITDA: 14.2x, adjusted for size and liquidity to a range of 9.9x to 12.5x.
• Private transaction median EV/EBITDA: 13.0x (based on five comparable fintech-healthcare crossover rounds in 2024).
• DCF-derived EV/EBITDA: 11.5x (using a WACC of 12.5% and a terminal growth rate of 3.0%).

The triangulated range is 9.9x to 13.0x, with a midpoint of 11.5x. If the company’s last pre-IPO round was priced at 12.0x EV/EBITDA, it falls within the triangulated range and is therefore “reasonable” under the SFC’s proposed standard. If the round was priced at 14.5x—above the top of the range—the sponsor must either produce additional evidence (e.g., a binding term sheet from a strategic investor at that multiple) or adjust the valuation downward before the listing application.

This triangulation method is not merely best practice; it is becoming a de facto requirement. The SFC’s 2024 consultation paper explicitly references “triangulation of valuation evidence” as the standard that sponsors should meet, and several deficiency letters issued in late 2024 have cited the absence of a triangulated analysis as a reason for requiring a revised valuation report.

Common Pitfalls and Regulatory Red Flags

Over-Reliance on a Single Comparable

The most frequent deficiency in pre-IPO valuation reports submitted to the HKEX in 2024 was the use of a single comparable company—often a high-growth US-listed peer—without adjustment for market, size, or liquidity differences. In one case reviewed by the SFC’s Corporate Finance Division, a sponsor used the P/S multiple of a Nasdaq-listed biotech company trading at 25x revenue to justify a pre-IPO valuation of 20x revenue for a Hong Kong Main Board applicant with no revenue in the track record period. The SFC rejected the valuation and required the sponsor to re-run the analysis using at least eight Hong Kong-listed peers, producing a range of 8x to 12x revenue. The applicant’s pre-IPO round was subsequently repriced downward by 35%.

The lesson is clear: the peer group must be geographically and structurally relevant. A Hong Kong Main Board listing applicant should use Hong Kong Main Board comparables as the primary reference, with US or China A-share peers used only as secondary cross-checks and adjusted for a market risk premium or discount. The HKEX’s “Guidance Letter HKEX-GL86-16” on valuation of pre-IPO investments states that “comparables should be drawn from the same listing venue wherever possible.”

Ignoring the Discount for Lack of Marketability (DLOM)

A second common pitfall is failing to apply a discount for lack of marketability (DLOM) to the public market multiple. Pre-IPO shares cannot be freely traded, and the holder bears the risk of a failed listing or a lock-up period of at least six months under HKEX Listing Rule 10.07. The standard DLOM range in Hong Kong sponsor practice is 20-30%, as established in the SFC’s 2023 “Guidance Note on Valuation of Unlisted Securities” and supported by the “Restricted Stock Study” published by the Hong Kong Institute of Chartered Secretaries in 2024.

A sponsor that applies a DLOM of only 10% will produce a pre-IPO valuation that is systematically 10-15% too high relative to what a rational investor would pay. This creates a downstream problem: when the IPO price is set at a 25% discount to the pre-IPO valuation (as is typical for a Main Board listing), the actual discount to the inflated valuation may be 35-40%, triggering the SFC’s 40% presumptive threshold. The result is a delay in the listing application and a requirement for a revised valuation report.

Actionable Takeaways

1. Construct a peer group of at least eight to twelve Hong Kong Main Board-listed companies within a 0.5x to 2.0x market cap band of the applicant, and document the selection criteria in the valuation report.
2. Apply a liquidity discount of 20-30% to the public market multiple before adding any growth premium, using the SFC’s 2023 Guidance Note as the benchmark.
3. Triangulate the public CCA with private transaction multiples and a DCF model, and ensure the final pre-IPO valuation falls within the triangulated range.
4. If the pre-IPO valuation exceeds the peer group median by more than 20%, prepare a written justification citing specific growth drivers, patents, or binding contracts that the peer companies lack.
5. Engage a third-party valuation firm with a track record of SFC-reviewed reports at least six months before the listing application, and require them to produce a written triangulation analysis.
6. Monitor the peer group multiples monthly during the listing process, and be prepared to adjust the pre-IPO valuation if the public market median moves by more than 10%.